Skip to Main content Skip to Navigation
Journal articles

First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?

Abstract : Therapy for Crohn's disease has long been based on a step-up approach, with monoclonal antibodies against TNF as a final option before surgery. Despite the introduction of these monoclonal antibodies, no major changes have occurred in the natural history of Crohn's disease, with half of all patients still requiring intestinal resection at 10 years. Labelling for anti-TNF agents does not take into account prognostic factors. In this Review, we propose that treatment of Crohn's disease be based on the following three disease stages: mild, moderate and severe. In patients with Crohn's disease who have complicated disease or bowel damage, and with poor prognostic factors and/or severe disease, anti-TNF treatment should be considered as first-line therapy. For patients living in areas of high risk of developing tuberculosis, as well as for patients with mild-to-moderate Crohn's disease without poor prognostic factors and with uncomplicated disease, steroids and thiopurine should be the first-line therapy. By treating patients with Crohn's disease in accordance with these disease stages, we might be able to alter disease course and reduce overtreatment. Upcoming disease-modification trials are expected to provide information to guide decision-making, ultimately changing the course of disease and improving patient quality of life.
Document type :
Journal articles
Complete list of metadata
Contributor : NGERE UL Connect in order to contact the contributor
Submitted on : Wednesday, February 7, 2018 - 10:47:25 AM
Last modification on : Tuesday, October 13, 2020 - 10:46:27 AM




Laurent Peyrin-Biroulet, Gionata Fiorino, Anthony Buisson, Silvio Danese. First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?. Nature reviews. Gastroenterology & hepatology, Nature Publishing Group, 2009-, 2013, 10 (6), pp.345 - 351. ⟨10.1038/nrgastro.2013.31⟩. ⟨hal-01702742⟩



Record views